Entering text into the input field will update the search result below Entering text into the input field will update the search result below ...

We are initiating coverage on Rocket Pharmaceuticals with a Buy rating and a $17 price target (2-3 years). The company has an enterprise value, EV, of $151M at present, a valuation that implied near ...